Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
10.68
-0.31 (-2.82%)
Nov 20, 2024, 4:00 PM EST - Market closed
Atara Biotherapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for ATRA stock have an average target of 26.88, with a low estimate of 11 and a high estimate of 57.5. The average target predicts an increase of 151.69% from the current stock price of 10.68.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for ATRA stock from 5 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Hold | 4 | 4 | 3 | 3 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 2 | 2 | 1 | 1 | 1 | 1 |
| Total | 7 | 7 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $13 → $21 | Strong Buy | Maintains | $13 → $21 | +96.63% | Nov 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Aug 21, 2024 |
| Mizuho | Mizuho | Hold → Buy Upgrades $25 → $18 | Hold → Buy | Upgrades | $25 → $18 | +68.54% | Aug 16, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $13 | Strong Buy | Maintains | $13 | +21.72% | Aug 13, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Sell Maintains $13 → $11 | Strong Sell | Maintains | $13 → $11 | +3.00% | Jul 17, 2024 |
Financial Forecast
Revenue This Year
110.66M
from 8.57M
Increased by 1,190.80%
Revenue Next Year
106.92M
from 110.66M
Decreased by -3.38%
EPS This Year
-7.69
from -65.18
EPS Next Year
-8.94
from -7.69
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 139.9M | 162.8M | 153.4M | ||
| Avg | 110.7M | 106.9M | 116.4M | ||
| Low | 74.7M | 54.9M | 66.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1,532.3% | 47.1% | 43.5% | ||
| Avg | 1,190.8% | -3.4% | 8.8% | ||
| Low | 771.1% | -50.4% | -37.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.59 | 1.89 | -0.60 | ||
| Avg | -7.69 | -8.94 | -0.58 | ||
| Low | -16.30 | -20.08 | -0.56 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.